Article Per Year (5 Year)
p-Index From 2021 - 2026
0.562
P-Index
This Author published in this journals
All Journal Journal of Endocrinology, Tropical Medicine, and Infectious Disease (JETROMI)
Ginting, Fransiscus
Unknown Affiliation
Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
D-Dimer Levels of COVID-19 patients with Diabetes Mellitus: a Retrospective study Dharma Lindarto; Ginting, Fransiscus
Journal of Endocrinology, Tropical Medicine, and Infectious Disease (JETROMI) Vol. 5 No. 2 (2023): Journal of Endocrinology, Tropical Medicine, and Infectious Disease (JETROMI)
Publisher : TALENTA Publisher, Universitas Sumatera Utara

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32734/jetromi.v5i2.10288

Abstract

Background: Diabetes is the commonest comorbidity in Coronavirus disease 2019 (COVID-19) patients, and D-dimer level assessment has reliable parameters for assessing and evaluating the prognosis of COVID-19 patients with comorbid. This study aims to compare D-dimer,  FPG, and PPG levels between COVID-19 patients with comorbid. Method: We conducted a retrospective descriptive and analytical study carried out at D-dimer, FPG, and PPG levels of COVID-19 patients with comorbid in a tertiary Hospital in Medan, Indonesia, from April 04, 2020, to November 22, 2020. The data were collected by cheek list, using electronic medical records. The data included age, gender, medical history, comorbidity disease inward, and ICU admission. All these cases of COVID-19 have been confirmed in the laboratory by Real-Time Reverse Transcription Polymerase Chain Reaction (RT-PCR). Result: From 323 COVID-19 patients with comorbidities, there are significant differences in D-dimer, FPG, and PPG levels between all groups of COVID-19 patients with the comorbid disease (p<0.05),  and there is a significant difference in D-dimer, FPG, and PPG level between severity of COVID-19 with comorbidities (p<0.005).     Conclusion: There is a significant difference between D-dimer, FPG, and PPG levels in COVID-19 patients with comorbidities in comorbid type and severity of COVID-19.
Correlation between Neutrophil to Lymphocyte Ratio (NLR) and D-Dimer In Patients Covid-19 with Diabetes Dharma Lindarto; Ginting, Fransiscus
Journal of Endocrinology, Tropical Medicine, and Infectious Disease (JETROMI) Vol. 5 No. 1 (2023): Journal of Endocrinology, Tropical Medicine, and Infectious Disease (JETROMI)
Publisher : TALENTA Publisher, Universitas Sumatera Utara

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32734/jetromi.v5i1.10318

Abstract

Abstract: Background: The neutrophil to lymphocyte ratio (NLR) has been proposed as an infammatory biomarker. Tujuan penelitian adalah menilai hubungan antara NLR dan D-dimer pada pasien Covid-19 dengan diabetes. Method: This is a retrospective descriptive and analytical study carried out at NLR, blood rutin and D-dimer, FPG, and PPG levels of COVID-19 patients with comorbid in H. Adam Malik Medan, Indonesia, from May 19, 2020, to Juny 08, 2021. The data were collected by cheek list, using electronic medical records. The data included age, gender, medical history, comorbidity with diabetics, and ward and ICU admission. All these cases of COVID-19 have been confirmed in the laboratory by Real-Time Reverse Transcription Polymerase Chain Reaction (RTPCR). Results: There were 163 COVID-19 patients with diabetes consisting FPG 241.65±122.23 mg/dl, PPG 286.01±123.92 mg/dl, and HbA1c 9.49±2.41%. There is a significant correlation between NRL and hemoglobin, white blood cells, platelets, neutrophils, and D-dimers (all, p<0.001*). Conclusion: Diabetes is the commonest comorbidity in COVID-19 patients, and NLR and the others inflammatory assessment have reliable parameters for assessing and evaluating the prognosis of the COVID-19 patients as well as an accurate and practical coagulation parameter for predicting mortality.
Predicting the Risk of Mortality for Patients Diabetic with Coronavirus Disease (COVID-19): A Retrospective study Dharma Lindarto; Ginting, Fransiscus
Journal of Endocrinology, Tropical Medicine, and Infectious Disease (JETROMI) Vol. 5 No. 1 (2023): Journal of Endocrinology, Tropical Medicine, and Infectious Disease (JETROMI)
Publisher : TALENTA Publisher, Universitas Sumatera Utara

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32734/jetromi.v5i1.10319

Abstract

Background. One of the biggest causes of mortality of patients diabetic with COVID-19 in the globe is diabetes mellitus. The study's goal was to examine the predicting the risk of mortality for patients diabetic with coronavirus disease (COVID-19). Methods. This is a retrospective study of patients diabetic with COVID-19 on 22 June 2020 to 21 July 2021 in H. Adam Malik Hospital Medan from 22 June 2020 to 21 July 2021. We collected all the data from electronic medical records on diabetics with SARS-CoV-2 infection, including demographic, clinical, laboratory, and radiological characteristics, treatments, complications, and clinical outcomes. All patients had throat swabs taken from their upper respiratory tracts to determine whether they had SARS-CoV-2 infection. Diagnosis of diabetes mellitus used ADA criteria. Results: There were 163 diabetic patients with COVID-19, consisting of mild (0%), moderate (39.8%), severe (44.2%), and critical (16.5%), and the most comorbid disease is hypertension. There was a significant age difference, length of stay, blood routine, and certain inflammatory markers between patients Diabetic with COVID-19 discharged from the hospital and died (all, p<0.05). The predicted death of patients diabetic with COVID-19 was D-dimer (OR: 4.069; p=0.008*;95% C.I: 1.43-11.55) and dexamethasone use (OR:4.769; p=0.007*; C.I: 1.54-14.71). Conclusion. The use of dexamethasone and the increase of D-dimer values increase mortality predictions in treating diabetic patients with COVID-19 in hospitals. To prevent these harms, the management of inpatients diabetic with COVID-19 must be with good glucose consideration and monitoring.
Co-Authors dharma Lindarto, dharma